The migraine market is comprised of an array of prescription acute and prophylactic treatments. Today, oral triptan products—the gold standard of acute treatment—already do, or will, face generic competition during our forecast period. Nevertheless, we expect the launch of several emerging therapies including promising nontriptan alternatives—among them Eli Lilly’s 5-HT1F receptor agonist, lasmiditan, and two calcitonin gene-related peptide (CGRP) receptor antagonists, Allergan’s ubrogepant, and Biohaven’s rimegepant—will support future growth in the large acute treatment segment. However, the launch of four premium-priced anti-CGRP MAbs for migraine prophylaxis in both episodic and chronic migraineurs will be the main driver of multi-billion-dollar sales growth in the market; these drugs follow in the footsteps of Allergan’s Botox, which showcases the commercial opportunity that new brands offering valued alternatives can seize in the otherwise generic prophylaxis segment.
- How will the anticipated launch of four anti-CGRPMAbs impact the migraine prophylaxis market? How will Amgen/Novartis’s Aimovig, Teva’s Ajovy, Eli Lilly’s Emgality, and Alder’s eptinezumab compete with one another, and with established prophylactic therapies, as their marketers vie for patient share?
- Will emerging nontriptan acute treatments, including Eli Lilly’s lasmiditan, Allergan’s ubrogepant, and Biohaven’s rimegepant, gain a foothold in the acute market against the entrenched and genericized triptan drug class?
- How will the launch of emerging acute and prophylactic migraine treatments impact diagnosis and drug-treatment rates over the forecast period?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.